Search: WFRF:(Walther Jallow L.) >
An exploratory open...
-
Sagar, Rachel LUniversity College London
(author)
An exploratory open-label multicentre phase I/II trial evaluating the safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe osteogenesis imperfecta in infants and fetuses: the BOOSTB4 trial protocol
- Article/chapterEnglish2024
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:d491b132-d3ed-4684-b038-89116f8e2ab9
-
https://lup.lub.lu.se/record/d491b132-d3ed-4684-b038-89116f8e2ab9URI
-
https://doi.org/10.1136/bmjopen-2023-079767DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Introduction Severe osteogenesis imperfecta (OI) is a debilitating disease with no cure or sufficiently effective treatment. Mesenchymal stem cells (MSCs) have good safety profile, show promising effects and can form bone. The Boost Brittle Bones Before Birth (BOOSTB4) trial evaluates administration of allogeneic expanded human first trimester fetal liver MSCs (BOOST cells) for OI type 3 or severe type 4.Methods and analysis BOOSTB4 is an exploratory, open-label, multiple dose, phase I/II clinical trial evaluating safety and efficacy of postnatal (n=15) or prenatal and postnatal (n=3, originally n=15) administration of BOOST cells for the treatment of severe OI compared with a combination of historical (1–5/subject) and untreated prospective controls (≤30). Infants<18 months of age (originally<12 months) and singleton pregnant women whose fetus has severe OI with confirmed glycine substitution in COL1A1 or COL1A2 can be included in the trial.Each subject receives four intravenous doses of 3×106/kg BOOST cells at 4 month intervals, with 48 (doses 1–2) or 24 (doses 3–4) hours in-patient follow-up, primary follow-up at 6 and 12 months after the last dose and long-term follow-up yearly until 10 years after the first dose. Prenatal subjects receive the first dose via ultrasound-guided injection into the umbilical vein within the fetal liver (16+0 to 35+6 weeks), and three doses postnatally.The primary outcome measures are safety and tolerability of repeated BOOST cell administration. The secondary outcome measures are number of fractures from baseline to primary and long-term follow-up, growth, change in bone mineral density, clinical OI status and biochemical bone turnover.Ethics and dissemination The trial is approved by Competent Authorities in Sweden, the UK and the Netherlands (postnatal only). Results from the trial will be disseminated via CTIS, ClinicalTrials.gov and in scientific open-access scientific journals.Trial registration numbers EudraCT 2015-003699-60, EUCT: 2023-504593-38-00, NCT03706482.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Åström, EvaKarolinska Institute
(author)
-
Chitty, Lyn SGreat Ormond Street Hospital
(author)
-
Crowe, Belinda
(author)
-
David, Anna LUniversity College London Hospital
(author)
-
DeVile, Catherine
(author)
-
Forsmark, AnnabellePharmaLex Sweden AB
(author)
-
Franzen, VeraXNK Therapeutics AB
(author)
-
Hermerén, GöranLund University,Lunds universitet,Medicinsk etik,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical Ethics,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)metk-ghe
(author)
-
Hill, Melissa
(author)
-
Johansson, MatsLund University,Lunds universitet,Medicinsk etik,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical Ethics,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)fil-mjo
(author)
-
Lindemans, CarolineUniversity Medical Center Utrecht
(author)
-
Lindgren, PeterKarolinska University Hospital
(author)
-
Nijhuis, Wouter
(author)
-
Oepkes, DickLeiden University Medical Centre
(author)
-
Rehberg, MirkoUniversity Hospital of Cologne
(author)
-
Sahlin, Nils-EricLund University,Lunds universitet,Medicinsk etik,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Vetenskap och Beprövad Erfarenhet (VBE),Forskargrupper vid Lunds universitet,Medical Ethics,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,VBE,Lund University Research Groups(Swepub:lu)fil-nes
(author)
-
Sakkers, Ralph
(author)
-
Semler, O
(author)
-
Sundin, Mikael
(author)
-
Walther-Jallow, Lilian
(author)
-
Verweij, EJT Joanne
(author)
-
Westergren, Magnus
(author)
-
Götherström, CeciliaKarolinska Institute
(author)
-
Karolinska InstituteUniversity College London
(creator_code:org_t)
Related titles
Internet link
Find in a library
-
BMJ Open
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Sagar, Rachel L
-
Åström, Eva
-
Chitty, Lyn S
-
Crowe, Belinda
-
David, Anna L
-
DeVile, Catherin ...
-
show more...
-
Forsmark, Annabe ...
-
Franzen, Vera
-
Hermerén, Göran
-
Hill, Melissa
-
Johansson, Mats
-
Lindemans, Carol ...
-
Lindgren, Peter
-
Nijhuis, Wouter
-
Oepkes, Dick
-
Rehberg, Mirko
-
Sahlin, Nils-Eri ...
-
Sakkers, Ralph
-
Semler, O
-
Sundin, Mikael
-
Walther-Jallow, ...
-
Verweij, EJT Joa ...
-
Westergren, Magn ...
-
Götherström, Cec ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Pediatrics
- Articles in the publication
-
BMJ Open
- By the university
-
Lund University